Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The author was supported by Sanofi. D Raccah is a member of advisory boards and speaker in symposia for Lilly, Novo Nordisk, Sanofi, MSD, BMS, Astra Zeneca, Merck Serono, Boehringer Ingelheim, Novartis. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript. The author would like to thank S Barnes, Caudex Medical (London, UK) for providing writing assistance, which was funded by Sanofi.